AMENDMENTS TO THE SPECIFICATION

Please replace paragraph [0363] on page 139 with the following amended paragraph:

As discussed ~~dicussed~~ above, in one aspect, the present invention provides methods for the preparation of Migrastatin and analogs thereof. Detailed below is a synthetic approach, which resulted in an efficient and flexible total synthesis of **1**. Additional guidance may be found, for example, in Gaul, C. et al.; *J. Am. Chem. Soc.* **2003**, *125*, 6042; and Gaul, C. et al.; *J. Am. Chem. Soc.* **2004**, *126(4)*, 1038-1040; ~~and Gaul, C. et al.; *J. Am. Chem. Soc.* **2004**, ___, ___;~~ each of which is hereby incorporated by reference in its entirety; and Gaul, C. et al.; *J. Am. Chem. Soc.* **2004**, *126 (36)*, 11326-11337. Migrastatin having known biological activity, it was expected that its analogs would exhibit similar activity. As discussed above, however, the present invention provides the ability to synthesize various migrastatin analogs with a variety of structural features; thereby allowing one to probe and evaluate Structure-Activity Relationships trends within this class of macrocyclic compounds. Preliminary SAR studies[28] have been reported. For example, guidance may be found in U.S. Provisional Application Nos.: 60/458,827 filed March 28, 2003 and 60/496,165 filed August 19, 2003; each of which are incorporated herein by reference. In a preliminary study, a few migrastatin analogs ~~which~~ were evaluated in both tube formation and wound healing assay (See Example 52 and Tables 1 and 2). In addition to two analogs closely structurally related to migrastatin (i.e., *N*-Methyl-migrastatin and 2,3-Dihydromigrastatin **(41)**), the question of how the migrastatin C-13 side chain might impact activity was investigated (cf. Migrastatin-Core **(45)**). One advantage of this type of compounds lies in the simplicity of their structure; they ~~They~~ are therefore easier to synthesize, less costly and more amenable to large scale preparation. Compound **45**, along with the other two migrastatin analogs were thus subjected to the aforementioned assays. A chamber cell migration assay was also proposed that could be used to screen and identify migrastatin analogs exhibiting cell migration inhibitory activity (See Example 52 and Table 3). Preliminary results are summarized in Tables 1-3 below.